Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 790

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 790
---
 Company agreed to pay the Placement Agent a cash fee of 7.0% of the gross proceeds, a management fee of 1.0% of the gross proceeds, and $ 50,000for accountable expenses. Additionally, the Company issued to the Placement Agent warrants to purchase up to 5,736Company Common Shares at an exercise price of $ 12.00per share. These warrants are exercisable from the date of issuance until five years from the commencement of sales in the offering. On March 20, 2024, the Company entered into a securities purchase agreement, or the Purchase Agreement, providing for the issuance in a registered direct offering of 175,000Company Common Shares at a purchase price of $ 10.00per share that closed on March 22, 2024. In addition, pursuant to the Purchase Agreement, the investors received unregistered warrants, or the Common Warrants, to purchase up to an aggregate of 87,500Company Common Shares at an exercise of $ 10.00per share in a concurrent private placement. The Common Warrants were immediately exercisable upon issuance and will expire five years following the date of issuance. The Company has also agreed that from the date of the Purchase Agreement until one year after the closing date of the offering, the Company shall not enter into an agreement to effect any issuance by the Company or any of the Company’s subsidiaries of Company Common Shares or common share equivalents (or a combination of units thereof) involving a variable rate transaction. The offering resulted in gross proceeds to the Company of $ 1,750,000and expenses of approximately $ 321,000. Warrants On October 9, 2024, the Company and certain existing warrant holders entered into warrant amendment agreements, or collectively, the Amendment, to amend those warrants issued by Company to such holders, collectively, to purchase up to 105,843Common Shares issued to such holders, or the Existing Warrants. The Amendment makes certain Annex F-23 NLS PHARMACEUTICS LTD. AND SUBSIDIARIES NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

adjustment to the definition of a “Fundamental Transaction” in Section 3(e) of the Existing Warrants. In exchange for the Amendment, the Company agreed to adjust the exercise price in the Common Warrants to CHF 0.80and issued to the holders Pre -FundedWarrants to purchase up to 136,648Common Shares, or the Pre -FundedWarrants